Predict your next investment

Venture Capital
new-lifescience.com

See what CB Insights has to offer

Investments

6

Portfolio Exits

1

Funds

1

About Shinsei Capital Partners

Shinsei Capital Partners focuses on investing in early-stage Japan-based startup companies engaged in life science fields such as biotech or digital health technology.

Shinsei Capital Partners Headquarter Location

2-chōme-4-3 Nihonbashimuromachi Chuo City

Tokyo, 103-0022,

Japan

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Shinsei Capital Partners News

Promethera Biosciences Completes 39.7 Million $44.4 Million Series D Financing

May 7, 2019

Promethera Biosciences SA , a global innovator in cell -based medicines and liver diseases, today announced the closing of a €39.7million (JPY4.94 billion) Series D financing. The round was co-led by new Japanese investors ITOCHU Corporation, who contributed €10 million to this financing in January, and Shinsei Capital Partners. MEDIPAL HOLDINGS CORPORATION (Japan), Mirae Asset Capital (Korea), the family office Six Snow (Luxembourg), Korea Investment Partners (Korea), Ci:z Investment LLP (Japan) are joining the round as well as Belgian private investors. Promethera’s existing investor, Mitsui & Co. Global Investment, Inc. (MGI) also participated in the financing. Proceeds from the financing will accelerate the company’s ongoing HepaStem clinical program in ACLF and the launch of the company’s first clinical trial in NASH. In addition, the funding will be used for its manufacturing scale-up, preclinical programs and overall operations of the company and the group. “The financial support of our new and existing investors, with their expertise in cell therapies and wide Asian and global networks, will greatly help us as we efficiently advance the world’s first cell-based treatment for ACLF and NASH through clinical trials,” said John Tchelingerian, PhD, President and CEO of Promethera. “Our clinical trial in late stage NASH will soon be initiated first in Europe and is expected to expand to the US and Asia. We are excited to see how our HepaStem drug candidate can make a difference in the lives of patients with severe liver diseases. Overall, we are looking at a transformational period for our company and the financing puts us in a great position to execute our plans.” “Promethera has taken great steps to increase and bolster our relations and operations in Asia, and specifically in Japan and Korea, so we can benefit from the openness to stem-cell therapeutics in this area of the world,” said Mutsuki Takano, Group CFO and General Manager of Promethera’s Japan branch. “This territorial move has already started showing results, with our shareholder base growing significantly in Asia not least through this financing round.” HepaStem consists of liver stem cells that are obtained from ethically donated healthy human livers and expanded under cGMP conditions in production. The product candidate is currently being evaluated in a phase 2a clinical trial in the indication ACLF with first safety and efficacy results being presented recently at The International Liver Congress 2019 (EASL) as part of a late-breaking oral presentation. In addition to its cell-based approaches, HepaStem and H2Stem, Promethera is advancing a portfolio of complementary biologics approaches including the anti-TNF-R1 antibody Atrosimab. About Promethera Biosciences Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring patients life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline (HepaStem and H2Stem), we develop antibody technologies such as the anti-TNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert (Belgium), Durham (NC, USA), Tokyo (Japan) and Basel (Switzerland). Promethera®, HepaStem®, H2stem® are all registered trademarks of the PROMETHERA group. View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005807/en/ Promethera Biosciences SA

Shinsei Capital Partners Investments

6 Investments

Shinsei Capital Partners has made 6 investments. Their latest investment was in Luxna Biotech as part of their Series B on December 12, 2021.

CBI Logo

Shinsei Capital Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/16/2021

Series B

Luxna Biotech

$10.73M

Yes

2

8/21/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

1/23/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

5/7/2019

Series D - II

Subscribe to see more

$99M

Subscribe to see more

10

3/29/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/16/2021

8/21/2020

1/23/2020

5/7/2019

3/29/2019

Round

Series B

Series B

Series A

Series D - II

Series B

Company

Luxna Biotech

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$10.73M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

10

10

10

Shinsei Capital Partners Portfolio Exits

1 Portfolio Exit

Shinsei Capital Partners has 1 portfolio exit. Their latest portfolio exit was FunPep on December 25, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/25/2020

IPO

1

Date

12/25/2020

Exit

IPO

Companies

Valuation

Acquirer

Sources

1

Shinsei Capital Partners Fund History

1 Fund History

Shinsei Capital Partners has 1 fund, including New Life Science I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/7/2019

New Life Science I

Multi-Stage Venture Capital

Open

$83.1M

1

Closing Date

2/7/2019

Fund

New Life Science I

Fund Type

Multi-Stage Venture Capital

Status

Open

Amount

$83.1M

Sources

1

Shinsei Capital Partners Team

1 Team Member

Shinsei Capital Partners has 1 team member, including current Managing Partner, Manabu Nakamura.

Name

Work History

Title

Status

Manabu Nakamura

Managing Partner

Current

Name

Manabu Nakamura

Work History

Title

Managing Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.